Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Profound Medical Corp. (PROF)

Profound Medical Q3 revenue rises 86% to $9.8 million; Fabian named next CEO

Positive Impact 4 of 5 earnings Written later

Profound Medical reported third-quarter 2026 revenue of approximately $9.8 million, up 86% year-over-year, and a net loss of about $7.7 million, or $0.21 per share, narrower than the prior-year quarter. The company projects full-year 2026 revenue of at least $25.0 million and announced that Richard Fabian will succeed Arun Menawat as CEO effective January 14, 2027.

Key points

  • Q3 2026 revenue of approximately $9.8 million, up 86% year-over-year; gross margin of 78% versus 74% a year earlier
  • Net loss improved 3% to approximately $7.7 million ($0.21 per share) from $8.0 million ($0.26 per share)
  • Full-year 2026 revenue projected at least $25.0 million; gross margin expected at 70% or higher
  • Richard Fabian becomes CEO effective January 14, 2027; Arun Menawat becomes Executive Chairman

The filing

CompanyProfound Medical Corp. (PROF)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:15 PM ET
Accession number0001171843-26-007182

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.